Vaccinex is advancing a pipeline of monoclonal antibody therapeutics for the treatment of some of the world’s most complex and difficult-to-treat disorders in neurology and oncology.  Its lead clinical programs are focused on inhibition of semaphorin 4D (SEMA4D), a novel target and an important biological effector whose expression is implicated in the progression of a number of neurological diseases and cancers.

Pepinemab, a monoclonal antibody targeting SEMA4D is Vaccinex’s most advanced clinical candidate and is currently being studied in clinical trials for Huntington’s Disease (HD) and non-small cell lung cancer (NSCLC).

Vaccinex also plans to evaluate pepinemab as a treatment for additional neurodegenerative disorders such as Alzheimers, and, potentially, amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS).

 

Click to download